Fig. 1: CDK13 is upregulated in ccRCC and correlates with unfavorable clinical outcomes.
From: CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA
a Box plot showing pan-cancer analysis of CDK13 mRNA expression across 33 tumor types versus non-tumor tissues (TCGA, unpaired samples). b Radar chart visualizing the same CDK13 pan-cancer expression pattern as in (a). c Comparative analysis of CDK13 levels between TCGA tumor samples and matched normal tissues. d, e CDK13 mRNA expression in TCGA-KIRC tumors versus normal tissues. d Paired analysis. e Unpaired analysis. f–j Association of CDK13 mRNA levels with tumor size (f), lymph node metastasis (g), distant metastasis (h), pathologic stage (i) and histologic grade (j) in TCGA patients with ccRCC. k Diagnostic ROC curve evaluating CDK13’s predictive value for ccRCC in the TCGA cohort. l RT–qPCR analysis of CDK13 mRNA in 35 paired ccRCC tumors and adjacent normal renal tissues (**P < 0.01, paired t test). m Hematoxylin and eosin (HE) staining of normal renal tissues and ccRCC specimens. n Immunohistochemical (IHC) staining of CDK13 in normal and ccRCC tissues. Scale bar, 100 μm. o CDK13 protein expression in KIRC tumors versus normal tissues from the CPTAC database. p Western blot analysis of CDK13 protein in four paired ccRCC tumors (T) and adjacent normal tissues (N). q, r CDK13 mRNA (RT–qPCR) (q) and protein (western blot) (r) levels in human renal tubular epithelial cells (HK-2) and ccRCC cell lines (A498, 786-O, OS-RC-2 and 769-P). Elevated CDK13 expression was observed in 786-O and 769-P cells (***P < 0.001 versus HK-2; one-way analysis of variance). (*P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant).
